apl. Prof. Dr. Markus Heppt

Medizinische Fakultät Department of Dermatology

Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study (2022) Thiem A, Mashhadiakbar P, Cussigh C, Hassel JC, Grimmelmann I, Gutzmer R, Schlaak M, et al. Journal article CHALLENGES OF NETWORK META-ANALYSIS FOR SAFETY OUTCOMES: THE ANALYSIS OF TIRBANIBULIN AGAINST COMMON TREATMENTS IN EUROPE FOR ACTINIC KERATOSIS (2022) Heppt M, Dykukha I, Chapman-Rounds M, Graziadio S, Edwards M Conference contribution ASSESSING SIMILARITY OF STUDIES FOR NETWORK META-ANALYSIS: THE USE OF FEASIBILITY ASSESSMENT AND SENSITIVITY ANALYSES TO ESTIMATE THE EFFICACY OF TIRBANIBULIN, A NEW DRUG FOR ACTINIC KERATOSIS (2022) Heppt M, Dykukha , Chapman-Rounds M, Graziadio S, Edwards M Conference contribution Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry (2022) Haist M, Stege H, Lang BM, Tsochataridou A, Salzmann M, Mohr P, Schadendorf D, et al. Journal article Melanoma 2.0. Skin cancer as a paradigm for emerging diagnostic technologies, computational modelling and artificial intelligence (2022) Vera J, Lai X, Baur A, Erdmann M, Gupta S, Gutta C, Heinzerling L, et al. Journal article, Review article Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives (2022) Heppt M, Gebhardt C, Hassel JC, Alter M, Gutzmer R, Leiter U, Berking C Journal article, Review article BISPECIFIC ANTIBODIES ENABLE SYNTHETIC AGONISTIC RECEPTOR T CELL THERAPY IN MELANOMA (2022) Benmebarek M, Maerkl F, Keyl J, Cadilha B, Geiger M, Karches C, Obeck H, et al. Conference contribution The quality of national skin cancer screening from the perspective of general practitioners: A questionnaire-based comparison between Saxony and Bavaria (SaBaScreen) (2022) Strasser C, Reinhardt L, Steeb T, Wessely A, Schelling J, Petzold A, Heppt M, et al. Conference contribution SOX10-based drug repurposing identifies novel therapeutic targets in uveal melanoma (2022) Wessely A, Kammerbauer C, Lischer C, Weich A, Vera J, Berking C, Heppt M Conference contribution In vitro assessment of checkpoint-induced cytokine levels as new tool in the therapeutic decision-making process after checkpoint-induced cytokine release syndrome in metastatic melanoma (2022) Kramer R, Bender-Säbelkampf S, Berking C, Heppt M, Erdmann M, Bosch-Voskens C Conference contribution